News & Updates
Filter by Specialty:
Debunking the myth: There is no ‘obesity paradox’, new data suggest
Using alternative anthropometric measurements, a post hoc analysis that used data from the PARADIGM-HF* trial debunked the BMI-related ‘obesity paradox’ in a large cohort of patients with chronic heart failure with reduced ejection fraction (HFrEF).
Debunking the myth: There is no ‘obesity paradox’, new data suggest
26 Jun 2023
Pembrolizumab well tolerated, effective in NSCLC with autoimmune disease
Use of pembrolizumab is well tolerated in nonsmall cell lung cancer (NSCLC) patients with previous autoimmune diseases, with a nonsignificant trend toward improved outcomes, reports a study.
Pembrolizumab well tolerated, effective in NSCLC with autoimmune disease
25 Jun 2023
Neutrophilia, leukocytosis tied to poor outcomes in paediatric liver abscess
In children with liver abscess, factors such as age-related leukocytosis, neutrophilia, elevated aspartate transaminase or alanine transaminase, and hypoalbuminaemia at presentation are significantly associated with poor outcomes, suggests a study.
Neutrophilia, leukocytosis tied to poor outcomes in paediatric liver abscess
23 Jun 2023
Mediterranean diet counselling may help counter overweight/obesity in the offspring
A personalized nutritional counselling targeting adherence to the Mediterranean diet (MD) during pregnancy may be an effective strategy against childhood overweight/obesity, findings from the PREMEDI study have shown.
Mediterranean diet counselling may help counter overweight/obesity in the offspring
23 Jun 2023
HK data: No correlation between ADHD medication prescriptions and poisoning events
No significant correlation is observed between prescriptions of medications for attention deficit/hyperactivity disorder (ADHD) and poisoning cases involving ADHD medications in Hong Kong, a descriptive analysis has shown.
HK data: No correlation between ADHD medication prescriptions and poisoning events
23 Jun 2023
Nivolumab-AVD superior to brentuximab vedotin-AVD for advanced stage Hodgkin lymphoma
Treatment with nivolumab (N) plus doxorubicin, vinblastine, and dacarbazine (AVD) leads to improved progression-free survival (PFS) relative to brentuximab vedotin (BV) plus AVD in patients with advanced stage classic Hodgkin lymphoma (HL), according to the results of the SWOG S1826 study, which was presented at the recent ASCO 2023.